iBio, Inc. Common Stock (IBIO)

Sep 28, 2026

iBio, Inc. (NASDAQ:IBIO) has received a consensus "Buy" rating from Wall Street analysts, with an average 12-month price target of $5.29, significantly above its current share price of $1.19. Institutional ownership has increased, and the biotechnology company, which uses AI and machine learning for antibody therapeutics, recently beat quarterly EPS estimates. Despite a "Sell" rating from one analyst, the majority of ratings are positive, with several analysts initiating or reaffirming "Buy" or "Outperform" ratings.

Sep 18, 2026

HC Wainwright has upgraded iBio (NASDAQ:IBIO) to a "strong-buy" rating, contributing to a generally positive outlook from analysts, with a consensus "Buy" rating and an average price target of $5.29. The biotechnology company recently surpassed earnings estimates, reporting a quarterly loss of $0.04 per share, $0.03 better than expected. Institutional investors are increasing their stakes, indicating growing confidence in iBio's future.

Sep 13, 2026

Wall Street Zen has downgraded iBio (NASDAQ:IBIO) from a "hold" to a "sell" rating, despite a broader analyst consensus of "Buy" with a $5.00 price target. The company's shares opened at $1.21, down 1.6%, and its market capitalization is approximately $77.5 million. iBio reported a quarterly loss of $0.04 per share, beating analyst estimates, and institutional investors own 7.9% of its stock.